Recent surveys suggest that the abuse of drugs, often in combination, is pervasive throughout society. Adverse consequences of drug abuse tend to be attributed to the single drug "most likely" to be responsible. This is frequently seen in fatality cases, particularly those involving opioids. However, it is difficult to determine the specific cause of death when multiple drugs are involved. Although enhanced toxicity of alcohol and other centrally acting drugs with opioids has been well established in animal studies, there is a paucity of data in well-controlled human studies. We evaluated 1014 fatality cases involving oxycodone (OXC) for evidence of enhanced toxicity associated with multiple drug-drug interactions. We previously reported on these cases, and we classified them by a standardized method into groups that distinguished cases unrelated to drug abuse from those related to drug abuse, cases that involved only OXC from cases involving multiple drugs, drug-induced fatalities from drug-related fatalities, and cases in which the specific drug product OxyContin | (oxycodone HCI controlled-release) Tablets were identified from cases where OxyContin was not identified. Our working hypothesis was that OXC in combination with other centrally acting drugs is more toxic than OXC alone, evidenced by the finding of lower mean blood concentrations of OXC in multiple-drug-induced deaths compared to single (OXC only)-drug-ioduced deaths. Assessment of blood levels determined by specific assay methodology (primarily gas chromatography-mass spectrometry) in these cases provided the following mean postmortem concentrations of OXC: multiple-drug-induced deaths, OxyContin identified, 0. 
Introduction
Over the last several decades, concomitant use of multiple drugs has become pervasive amongst many drug-abusing populations. Darke and Hall (1) and others (2) (3) (4) (5) (6) (7) (8) have noted that illicit heroin and amphetamine abusers rarely restrict their drug use to one primary drug. The reasons for the emergence of polydrug abuse behavior are complex. Clayton (9) concluded from studies of multiple drug users that "there is substantial and growing evidence that a large minority, perhaps a majority of drug abusers, regularly ingest multiple substances simultaneously in order to enhance the effects of the drugs they are taking, to counteract the effects of one drug with another, or to use one or more drugs as substitute for drugs that are not available."
Unfortunately, the consequences of the abuse of multiple drugs, especially in combination with opioids, can lead to serious toxicity, including death. The depressant effects of opioids, especially the effects on respiratory'drive, can be exaggerated and prolonged by other drugs, particularly those with central nervous system depressant effects. Combinations of opioids with tricyclic antidepressants, phenothiazines, and monoamine oxidase inhibitors may result in supra-additive effects (10) . Numerous other drugs including alcohol are also known to enhance the toxicity of opioids (11) (12) (13) (14) (15) . The mechanisms of these effects are not fully understood, but they may involve alterations in the pharmacokinetic properties of opioids, alterations in neurotransmitters involved in the actions of opioids, or combined effects on physiological systems involved in drug actions (16) .
The toxic interactive effects of opioids with other drugs is evident in animal studies (12) (13) (14) (15) 17) and in reports of opioid overdose fatalities (1) (2) (3) (4) (5) (6) (7) (18) (19) (20) (21) (22) (23) (24) . The 2001 Drug Abuse Warning Network (DAWN) mortality report (25) noted that 89% of deaths involving heroin/morphine also had mentions of at least one other drug. Similar findings were also reported for other opioid analgesics such as methadone, codeine, oxycodone (OXC), and hydrocodone. Our recent study of OXC involvement in drug abuse deaths found the vast majority of cases (889 out of 919, 96.7%) involved multiple drugs (26) . An average of 3.5 drugs in addition to OXC was identified by toxicology testing in the 889 cases of multiple drug abuse. The most prevalent drugs used in combination with OXC were benzodiazepines, alcohol, cocaine, other opioids, marijuana, and tricyclic antidepressants. A similar finding of multiple drug abuse was reported earlier by Drummer et al. (27) in a study of nine deaths involving OXC.
Despite overwhelming evidence that simultaneous abuse of multiple drugs in combination with opioids can result in greater toxicity than when opioids are abused alone, it is virtually impossible to document such toxic drug-drug interactions in controlled human dosing studies. The lack of basic information on multiple drug toxicities complicates even further the Medical Examiner's or Coroner's (ME/C) determination of cause of death (COD) in such cases. In the absence Of controlled clinical trial data, alternative methods for evaluating drug-drug interactions at toxic levels in humans are needed. Evaluation of drug concentrations in fatality cases involving single-and multiple-drug death could provide a means of obtaining such evidence.
In this report, our working hypothesis was that OXC abused in combination with other centrally acting drugs results in greater toxicity than the abuse of OXC alone. Evidence supporting this assumption would be the finding of lower concentrations of OXC in multiple-drug-induced, drug-abuse deaths compared to single-drug-induced, drug-abuse deaths. We tested the hypothesis by evaluating mean OXC blood concentrations in fatality cases of 919 drug abusers in an Oxycodone Postmortem Database (OPD) compiled systematically and classified using a system of categorization based on DAWN (26) . Primary comparisons of OXC blood concentrations were made between those cases involving multiple-drug abusers (one or more centrally acting drugs that could plausibly contribute to fatal outcome identified in addition to OXC) and those cases in which OXC was the sole drug reported on toxicology testing. A secondary objective of this analysis was to provide further characterization of the highly varied patterns of multiple drug use observed in the OPD.
Methods

Oxycodone postmortem database
The OPD was created from 1243 solicited cases from ME/C offices in 23 states in the United States involving deaths during the period from August 27, 1999, through January 17, 2002. The request for cases was specific to only those in which the ME/C opined that the death involved OXC. Each case was evaluated to determine the role of OXC and the specific drug product OxyContin (oxycodone HCI controlled-release) tablets in the death. OXC identification was based on toxicology testing. OxyContin identification was based on evidence found at the scene, credible witness reports, identification of intact tablets on or in the decedent, or identifiable fragments or so-called "ghost tablets" (empty tablet matrices) in gastrointestinal contents. A case was classified as a drug-abuse death if any of the following criteria were met: drug paraphernalia found at the death scene, credible witness report, confirmed history of drug abuse, physical stigmata of drug abuse (e.g., tracks or "skin popping" scars), or illicit drugs identified on postmortem toxicology. A system of case categorization was developed for this study based on the DAWN system for reporting drug abuse mortality data in the United States. Eleven groups were created that allowed disaggregation of mortality cases into specific groups as follows: Group 0, incomplete, cannot be evaluated; Group 1, no OXC reported; Group 2, OXC present, but COD unrelated to drug abuse; Group 3, multiple-drug-induced, drug-abuse death, OxyContin identified; Group 4, multiple-drug-induced, drug-abuse death, involving OXC, OxyContin not identified; Group 5, multiple-drug-related, drug-abuse death, OxyContin identified; Group 6, multiple-drug-related, drug-abuse death involving OXC, OxyContin not identified; Group 7, OXC drug-induced, drug-abuse death, OxyContin identified; Group 8, OXC druginduced, drug-abuse death, OxyContin not identified; Group 9, OXC drug-related, drug-abuse death, OxyContin identified; and Group 10, OXC drug-related, drug-abuse death, OxyContin not identified. Of the 1243 cases, 79 cases were incomplete (Group 0), and an additional 150 cases were submitted in which OXC was not reported by the originating ME/C (Group 1), despite the request for only those cases involving OXC. Of the remaining 1014 cases, 919 were related to drug abuse, whereas 95 cases were categorized as not involving drug abuse (Group 2). The 919 drug abuse cases were categorized as follows: Group 3, N = 177; Group 4, N = 646; Group 5, N = 12; Group 6, N = 54; Group 7, N = 12; Group 8, N = 16; Group 9, N = 0; and Group 10, N = 2. The results of the DAWN-based categorization of the cases have been reported previously (26) .
Toxicological analyses
All available toxicology results of the 1243 cases were compiled in the OPD. Frequently, there were data on multiple fluids and tissues. Distinction was made between specific chromatographic assay data and immunoassay results. Immunoassay resuits were not considered sufficiently specific for inclusion in this study. Nearly all quantitative assays involved drug measurement by gas chromatography-mass spectrometry (GC-MS); however, quantitative results were not always reported, and, in some cases, only qualitative results were available.
Mean drug concentrations in "blood" specimens were derived by averaging results across selected groups. The specimens identified as postmortem "blood" were collected at autopsy from various anatomical sites. In a few cases, specimens were described as "chest fluid", "body cavity fluid", "liver fluid", "pleural fluid", and "kidney fluid". If a blood specimen accompanied these specimens, it was used preferentially. If no blood specimen was present, the "fluid" specimen was included in the analysis. If multiple blood test results were available, the specimen with the highest OXC concentration was selected. Also, toxicological test results infrequently contained quantitative drug results for "free" blood and "total" blood. When both resuits were available, the specimen with the highest OXC concentration was included in statistical summaries.
Initial statistical evaluation of OXC blood concentrations in the OPD revealed the presence of four outlier values. These four cases had the following characteristics: female, 48 years of age, suicide, Group 3, 60 lJg/mL OXC; female, 46 years of age, suicide, Group 4, 59.8 gg/mL OXC; female, 34 years of age, accident, Group 4, 65 lJg/mL OXC; and male, 35 years of age, Journal of Analytical Toxicology, Vol. 28, October 2004 suicide, Group 5, 46 gg/mL OXC. To prevent skewing of mean data, these four cases were not included in mean summaries of OXC blood concentrations.
Statistics
Toxicological concentrations are presented using descriptive statistics, including means, standard errors, medians, interquartile ranges, and minimum and maximum values. Comparisons between groups were conducted using non-parametric t-tests (Kruskal-Wallis) because of the large discrepancies between the numbers of cases associated with each group.
Results
OXC postmortem blood concentrations
Mean OXC blood concentrations by DAWN Groups 2-10 are shown in Table I . Generally, mean OXC blood concentrations were lower for multiple-drug-induced, drug abuse deaths (Groups 3 and 4) than for single drug-induced, drug abuse deaths (Groups 7 and 8) and higher for drug-induced (Groups 3, 4, 7, and 8) than for drug-related cases (Groups 5, 6, and 10). Nonparametric (Kruskal-Wallis) comparisons of DAWN Groups 3 versus 7 and 4 versus 8 indicated no significant difference for Group 3 versus 7; however, the difference for Group 4 versus 8 was significant (p < 0.05). Cases that were categorized as "Unrelated to drug abuse" (Group 2) had the lowest mean OXC blood concentrations. Overall, mean OXC concentration trends for the DAWN Groups were as follows: single (OXC alone)-drug-induced, drug-abuse deaths > multiple-drug-induced, drug-abuse deaths > drug-related, drug-abuse deaths = deaths unrelated to drug abuse; and OxyContin-identified deaths = OxyContin-not identified deaths.
A further tabulation of mean OXC blood concentrations by manner of death (MOD) for the DAWN Groups is shown in Table II . Generally, suicides had the highest mean OXC blood concentrations of all groups. Overall, mean concentration trends by MOD were as follows: Suicide > Accident = Undetermined > Natural. 
Evidence of enhanced drug toxicity by multiple drug abuse practices
A total of 823 drug abuse cases were categorized in the OPD as multiple-drug-induced deaths (Groups 3 and 4) and 28 as OXC-only drug-induced deaths (Groups 7 and 8). Evidence of enhanced toxicity of multiple drug abuse was derived from comparisons of OXC blood concentrations in the multipledrug-induced groups (Groups 3 and 4) to the single drug-induced groups (Groups 7 and 8). As shown in Table I , the mean (median = 50th percentile) OXC blood concentrations for Groups 3 and 4 were 0.93 (0.58) I~g/mL and 0.73 (0.40) IJg/mL and for Groups 7 and 8 were 1.55 (0.74) lJg/mL and 1.70 (0.65) ~g/mL, respectively. Thus, mean OXC concentrations for the single (OXC alone)-drug-induced groups were 1.67 and 2.33 times higher, respectively, than the multiple-drug-induced groups (comparison of Group 3 versus 7 and 4 versus 8).
A further comparison of Groups 3 and 4 to Groups 7 and 8 is shown in Figure 1 . OXC blood concentrations for suicide deaths are shown separately from other MODs (combined accidental, undetermined and natural). The mean OXC blood concentration for the combined, single-drug-induced suicide group (Groups 7 and 8) was 1.91 higher than the combined, multiple-drug-induced suicide group (Groups 3 and 4). A similar ratio was observed for the single-drug-induced (other MOD categories) compared to the multiple-drug-induced (other MOD categories).
To evaluate the effect of multiple drugs on OXC blood concentrations, mean OXC blood concentrations for cases in Groups 7 and 8 (no additional drug) were compared with Groups 3 and 4 in which there was one additional drug or multiple additional contributory drugs (two through six+, where six+ denotes cases with 6 to 13 drugs) present (Figure 2 ). In this evaluation, there was no restriction on the specific drug included; hence, in each multiple drug category, the drug(s) could be any one or more of the over 135 plausibly contributory drugs identified. All multiple drug combinations demonstrated consistently lower mean OXC concentrations than those cases in which OXC was the only drug identified (Groups 7 and 8). Figure 3 illustrates OXC blood concentrations for those cases in Groups 3 and 4 in which OXC and a single other drug was identified. In this comparison only OXC and one other drug were identified in toxicological testing. The overall mean OXC concentration for these cases was 0.71 IJg/mL (N = 90) as compared to 1.64 IJg/mL (N ---27) for the cases in the single druginduced groups (Groups 7 and 8). For example, the mean OXC blood concentration was 0.22 IJg/mL for Groups 3 and 4 when OXC was present in combination with methadone as compared 
. Figure 4 provides a more complex analysis of OXC-drug combinations. This figure illustrates mean OXC blood concentrations for Groups 3 and 4 for cases in which OXC was present in combination with another drug or multiple drugs (in any tissue), in this comparison, other "contributory" drugs could have been present, along with the specified OXC drug combination. For example, the mean OXC blood concentration was 0.27 pg/mL for Groups 3 and 4 when methadone was present as compared to 1.64 pg/mL for Groups 7 and 8 (no other drugs present). Note that numerous other contributory drugs could have been present along with methadone in this particular comparison. Generally, the presence of additional opioids (possibly in combination with multiple other drugs) demonstrated the lowest mean OXC blood concentrations. In this comparison, combinations of OXC with ethanol, benzodiazepines, antidepressants, and muscle relaxants were also associated with lower OXC blood concentrations in comparison to those cases containing solely OXC. 
Drug abuse patterns in multiple-drug-induced deaths
For cases in Groups 3 and 4 (multiple-drug-induced), in addition to OXC, over 135 plausibly contributory drugs were identified in body fluids and tissues by specific toxicological test methods. In individual cases, the number of drugs in addition to OXC ranged from 1 to 13; the overall average number of additional drugs was 3.5. Many drug combinations were present in these cases. 
Discussion
Although most ME/C and forensic toxicologists continue to use tables of reference values for "therapeutic" and "toxic" drug concentrations in interpretation of postmortem toxicology results involving opioids, it is evident that this approach has serious shortcomings. A plethora of factors affect postmortem opioid concentrations including premortem drug tolerance, postmortem redistribution, and additive/synergistic toxicity (28) . Currently, there are more than 20 different opioid analgesic substances available commercially in the United States, and additional ones are available in other countries. Many are available in different strengths, and some are compounded with other drug products. Although many of the opioids have prototypic mu opioid receptor agonist properties, some have actions on other opioid receptors (10) . Abusers who selfadminister these drugs are generally aware of the risks of opioid overdose, but frequently are not cognizant of the additional risks that arise from concomitant use of other drugs. Opioidinduced toxicity generally occurs through central effects by depression of respiratory drive. Combinations of opioids with other medications significantly increase the risk of fatality through additive or synergistic effects on the respiratory center or higher centers (10) .
OXC, a prototypical mu opioid agonist, is a pure opioid analgesic whose actions are similar to morphine. As is the case with other opioids, fatalities involving the abuse of OXC in combination with other drugs have increased significantly over the last decade (26) . The most frequently cited OXC combinations are with benzodiazepines, alcohol, cocaine, other opioids,
Table III. Occurrences of Other Plausible Contributory Drugs in Combination with OXC in the Multiple-Drug-Induced Categories (Groups 3 and 4)
marijuana, and antidepressants. Multiple-drug combinations appear to be common. An average of 3.5 additional drugs in addition to OXC were present in the 889 multiple drug fatalities in the OPD study (26) .
In the current analysis, evidence of enhanced toxicity from multiple drug use was assessed by an evaluation of OXC blood concentrations in selected groups. Toxicology test results for the groups were evaluated from several standpoints. Average OXC Oxycodone toxicity 1149 0.01 pg/mL OXC, blood (cava); 0.29 pg/mL OXC, blood (cava); 0.07 pg/g OXC, liver; 0.59 pg/g OXC, liver; 14.0 pg/mL OXC, urine; 0.30 pg/mL hydrocodone, urine; 0.32 pg/mL diazepam, blood (cava); 0.02 pg/mL cocaine, blood (cava); 0.45 pg/mL cocaine, blood (cava); 0.07 pg/mL codeine, urine; 10.0 pg/mL gamrnahydroxybutyrate (GHB), blood (cava); positive GHB, urine 639 Oxycodone toxicity 0.38 pg/mL OXC, blood (heart); 0.42 pg/mL OXC, spinal fluid; 0.40 pg/g OXC, liver; 0.06 g/dL ethanol, blood (heart); 0.07 g/dL ethanol, blood (heart2); 0.01 pg/mL amitriptyline, blood (heart); 0.19 pg/g amitriptyline, liver; 0.04 pg/mL nortriptyline, blood (heart); 0.74 pg/g nortriptyline, liver; 11.6 pg/mL meprobamate, blood (heart); 3.4 pg/mL carisoprodol, blood (heart); 1.60 pg/mL phenytoin, blood (heart); 1.80 pg/mL phenytoin, blood (heart 2); 5.8 pg/mL methanol, blood (heart) blood concentrations in multiple-drug-induced groups ranged from 0.73 lag/mL to 0.93 lag/mL. In contrast, OXC blood concentrations for the single-drug-induced groups ranged from 1.55 lag/mL to 1.70 IJg/mL (Table I) . As expected, suicide deaths generally had higher OXC blood concentrations than other MODs (Table II) . Mean OXC blood concentrations for suicide and other MODs for the multiple-drug-induced groups (Groups 3 and 4) were lower than those found for the single drug-induced groups (Groups 7 and 8) (Figure 1) . A further evaluation of mean OXC blood concentrations in the multiple-drug-induced groups was made by sorting cases into the number of additional centrally acting drugs identified by toxicology testing (Figure 2 ). All multiple-drug cases demonstrated lower OXC blood concentrations as compared to the single-drug-induced cases. With the exception of those cases with four additional drugs, most cases had mean OXC blood concentrations approximately 50% lower than the single-druginduced groups. The cases with four additional drugs had mean OXC blood concentrations approximately 30% lower than the single drug-induced groups.
Further assessments of enhanced toxicity of OXC in the current analysis were made by consideration of the type of drug combinations encountered in the multiple-drug-induced groups. Cases of OXC in combination with other opioids, benzodiazepines, antidepressants, muscle relaxants, and other drugs were identified and compared with cases in the singledrug-induced groups (Figures 3 and 4) . Mean OXC blood concentrations for all OXC-other drug combinations were lower by 50% or more than the OXC-only groups. Thus, all findings of this analysis were consistent with the hypothesis that lower average OXC blood concentrations would be present in those deaths involving multiple-drug abuse compared to cases in which OXC was the sole drug entity identified at autopsy.
Although the data in this report support the hypothesis that OXC in combination with other centrally acting drugs is more toxic than in those cases involving solely OXC, the findings are limited by several factors. The cases were not solicited on a random basis (only cases involving oxycodone were sought), and the results cannot necessarily be extrapolated to the entire United States, as case acquisition method was not intended to statistically represent the cases of all ME/Cs. Further, the number of cases in which OXC was the sole entity (Groups 7 and 8, single drug-induced groups) was considerably smaller than the multiple drug abuse groups (Groups 3 and 4, multipledrug-induced groups). Also, the possibility exists that additional drugs not identified by toxicology testing were involved in those drug-induced cases identified as involving solely OXC (Groups 7 and 8), as well as in other groups. Depending on survival time after drug administration, some drugs could have been sufficiently cleared by individuals prior to death, and hence, not detected in toxicology testing at time of autopsy. Drummer et al. (27) suggested that postmortem OXC concentrations may be influenced by accumulation following repeated use and/or postmortem redistribution. In addition, the complexity of drug patterns in the multiple-drug-induced groups limited the number of direct comparisons of cases in which specific multiple drug combinations could be made (e.g., Figure 3) .
Finally, all cases in this study were fatality cases, and it is not known whether the absence of one or more drugs considered as plausible contributory drugs would have altered the outcome and allowed the individual to survive.
The multiple drug abuse patterns found in this study are consistent with other reports of polydrug abuse patterns reported for opioids (1) (2) (3) (4) (5) (6) (7) (8) 27, 29) . Recent drug use surveys indicate that multiple-drug abuse is pervasive throughout society, but often there is a tendency to attribute consequences of drug abuse to the drug "most likely" to be responsible. Regarding the complexity of interpretation of multiple drug use, Clayton (9) stated that "Multiple drugs may mean multiple causes of impairment or exacerbated impairment over and above the level of impairment that would result had only one drug been used." This view carries over to interpretation of causes of death involving opioids. Deaths involving opioids are frequently attributed to the opioid identified at the highest concentration at autopsy with less regard for additional drugs that may have been present, often in the absence of clinical history that would shed light on the degree, if any, of tolerance to the respiratory depressant effects of opioids that result from repeated or regular exposure to opioids, either therapeutically or nonmedically.
In this study, many ME/Cs recognized the problem of attributing cause of death to a single drug and frequently utilized terms such as "Polydrug Abuse" and "Polypharmacy" in their COD statements. Over 70% of the COD statements for Groups 3 and 4 (multiple-drug-induced groups) contained either specific or nonspecific references to multiple drug use (26) . On the other hand, there were approximately 85 cases in the multipledrug-induced groups (Groups 3 and 4) where multiple drugs were involved and the COD statement identified OXC as the sole entity. Clearly, drug-related deaths are complex; COD statements often result from deductive reasoning in the absence of anatomic or medical cause. Drug deaths are not generally defined by pathologic lesion; thus, the presence of drugs and the history of drug use becomes paramount in interpretation. Importantly, use of a limited history and/or partial toxicology will restrict reaching a valid conclusion. To highlight these issues, we present 12 case examples in Table IV indicating the ME/Cs' COD and the complete results of the accompanying toxicology report. Although the ME/Cs' statements in these cases attributed the COD solely to OXC, it is apparent that multiple drugs were likely involved. Clearly, there is a lack of consistency by ME/Cs in assigning COD in multiple-drug cases involving opioids. Such examples should be avoided in favor of use of uniform nomenclature for assigning COD.
Conclusions
The significant additive and synergistic effects of opioids in combination with other centrally acting drugs demonstrated in animal studies appear to be equally applicable to humans who abuse opioids with other drugs. OXC, a prototypic mu opioid agonist, in combination with other drugs was found at autopsy in lower average blood concentrations than in fatality cases in which OXC was the sole drug entity. Consistent with the DAWN approach, it is concluded that in cases of multiple drug death fatalities, no single drug should be interpreted as the sole COD. Rather, it is the unique combination of drugs, drug use patterns, and individual factors, such as the degree of tolerance to respiratory depressant effects of opioids that must be taken into account in arriving at a valid COD statement.
